Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Philip Earwaker"'
Autor:
Philip Earwaker, Caroline Anderson, Frances Willenbrock, Adrian L Harris, Andrew S Protheroe, Valentine M Macaulay
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0191890 (2018)
The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. Here, we aimed to understand how RCC ce
Externí odkaz:
https://doaj.org/article/a518e79ae27440dca778a61503dee383
Publikováno v:
BMC Gastroenterology
Background In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival. However, similar to other tyrosine kinase inhibitors, most patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52df3dc19f6dfe060b56acc4d4017e54
https://doi.org/10.1186/s12876-017-0585-x
https://doi.org/10.1186/s12876-017-0585-x
Publikováno v:
Cancer Research. 75:3593-3593
Advanced renal cell cancer (RCC) is incurable, but recent advances in targeted treatment have improved the prognosis. Rapalogue inhibitors of the mammalian target of rapamycin (mTOR) are licensed for treatment of advanced RCC, although clinical benef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e997ffeb8fb8953f4d54250c5f8ec30f
https://doi.org/10.1158/1538-7445.am2015-3593
https://doi.org/10.1158/1538-7445.am2015-3593